Axitinib.
In patients with advanced-stage or metastatic kidney cancer, interferon alfa, a cytokine, prolongs survival by about 4 months, and sunitinib, a tyrosine kinase inhibitor, by about 9 months. When interferon alfa fails, sorafenib, another tyrosine kinase inhibitor, appears to prolong survival by an additional 3 months. There is currently no treatment that prolongs survival after failure of sunitinib.